Infliximab in the treatment of Crohn's disease - A practical approach - Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the ÖGGH;Infliximab in der therapie des Morbus Crohn - Ein praktischer leitfaden - Infliximab und Morbus Crohn - Konsensuspapier der Arbeitsgruppe Chronisch-Entzündliche Darmerkrankungen der ÖGGH

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 10, 2004, Pages 1256-1263

  Tilg, Herbert ^a   Knoflach, P ^b   Petritsch, W ^c   Vogelsang, H ^d   Reinisch, W ^d  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY HOSPITAL GRAZ   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLOSPORIN A; DIPHENHYDRAMINE; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PARACETAMOL; PREDNISOLONE; STEROID; TACROLIMUS;

ABDOMINAL ABSCESS; ARTICLE; BREAST CARCINOMA; BRONCHOSPASM; CHRONIC INFLAMMATION; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; HISTOPLASMOSIS; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUPUS ERYTHEMATOSUS; MELANOMA; NONHODGKIN LYMPHOMA; PNEUMONIA; REMISSION; SEPSIS; SIDE EFFECT;

ALGORITHMS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; REMISSION INDUCTION;

EID: 8444234311     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813567     Document Type: Article

References (39)

1. Reinisch W, Dejaco C, Knoflach P et al. Immunsuppressiva in der Therapie chronisch-entzündlicher Darmerkrankungen. Z Gastroenterol 2004; 9: 1033-1045
2. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443-448
3. Ten Hove T, van Montfrans C, Peppelenbosch MP et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-211
4. Lugering A, Schmidt A, Lugering N et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121: 1145-1157
5. Di Sabatino A, Ciccocioppo R, Cinque B et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53: 70-77
6. Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1610
7. Van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135
8. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035
9. D'Haens G, van Deventer SJ, van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-1034
10. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
11. Rutgeerts P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-769
12. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-413
13. Sartor RB. Episodic retreatment versus scheduled maintenance therapy for Crohn's disease with infliximab: not so far apart. Gastroenterology 2004; 126: 598-600
14. Pearson DC, May GR, Pick GH et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123: 132-142
15. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405
16. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885
17. Fiocchi C. Closing fistulas in Crohn's disease - should the accent be on maintenance or safety? N Engl J Med 2004; 350: 934-936
18. Van Bodegraven AA, Sloots CE, Felt-Bersma RJ et al. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 2002; 45: 39-45
19. Van Assche G, Vanbeckevoort D, Bielen D et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003; 98: 332-339
20. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45: 771-775
21. Miehsler W, Reinisch W, Kazemi-Shirazi L et al. Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis 2004; 10: 36-40
22. Herfarth H, Obermeier F, Andus T et al. Improvement of arthritis and arthralgia after treatment with infliximab in a German prospective, open-label, multi-centre trial in refractory Crohn's disease. Am J Gastroenterol 2002; 97: 2688-2690
23. Colombel JF, Loftus EV, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31
24. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104
25. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-155
26. Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-1324
27. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608
28. Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduves antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-924
29. Vermeire S, Noman M, van Assche G et al. Autoimmunity associated with anti-tumor necrosis factor a treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32-39
30. Klapman JB, Ene-Stroescu D, Becker MA et al. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003; 9: 176-178
31. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533
32. Sachmechian A, Vasiliauskas EA, Abreu MT et al. Malignancy following Remicade therapy. Incidence and characteristics Gastroenterology 2001; 120 (Suppl 1): 3144
33. Bickston SJ, Lichtenstein GR, Arseneau KO et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 1999; 117: 1433-1437
34. Bernstein CN, Blanchard JF, Kliewer E et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854-862
35. Andus T, Stange EF, Höffler D et al. Verdachtsfälle schwerwiegender Nebenwirkungen nach Infliximab aus Deutschland. Med Klin 2003; 98: 429-436
36. Wenzl HH, Reinisch W, Jahnel J et al. Austrian infliximab experience in Crohn's disease: a nation-wide cooperative study with long term follow up. Eur J Gastroenterol Hepatol 2004; 16: 767-773
37. Arnott IDR, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-1457
38. Lichtenstein GR, Stein R, Lewis JD et al. The presence of intestinal strictures is associated with poorer responses for active or fistulizing Crohn's disease. Am J Gastroenterol 1999; 94: 2676-2681
39. Mow WS, Abreu-Martin MT, Papadakis KA et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 4: 309-313